This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LEON H. GRIGGS, M.D.; JAY F. SCHAMBERG, M.D.

Arch Derm Syphilol. 1934;29(5):645-652.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the last few years, acetarsone, chemically known as 3-acetyl-amino-4-hydroxyphenyl-1-arsonic acid, appears to have established a place among the prominent therapeutic agents in the treatment of syphilis. It has been more extensively used abroad than in this country. It is known also as stovarsol. The formula or preparation was developed by Ehrlich¹ in 1911. It is believed that he was not satisfied with the practical therapeutic value of the preparation because of its toxic reactions in experiments with mice. No further study of the compound was made until its reinvestigation by Fourneau² in 1921.

In 1922, Levaditi and Navarro-Martin³ proved that acetarsone, injected subcutaneously in doses of from 0.1 to 0.2 Gm. per kilogram of body weight, has a curative action in experimental syphilis of the rabbit. In addition, Levaditi and Navarro-Martin⁴ found that the oral administration of the preparation brings about the healing of syphilitic . . . [Full Text PDF of this Article]

Author Affiliations
SYRACUSE, N. Y.; PHILADELPHIA

Footnotes
This thesis was submitted by L. H. G. to the Faculty of Dermatology-Syphilology of the University of Pennsylvania in partial fulfilment of the requirements for the degree of Master of Medical Science for graduate work in dermatology and syphilology.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?